Condition: Germ Cell Tumor · Sponsor: N.N. Petrov National Medical Research Center of Oncology
This is a prospective, single-center, non-randomized phase II study. Patients with germ cell tumors of gonadal and extragonadal localization who have progressed after prior platinum-containing first-line chemotherapy will receive high-dose chemotherapy with TI (2 cycles) folollowed by high dose CE chemotherapy with autologous stem cell transplantation (3 cycles). The primary endpoint of the study is to evaluate the efficacy high-dose chemotherapy as second-line drug therapy for patients with advanced germ cell tumors.
This description comes directly from the study's public registry record.
Anna Semenova, MD, PhD · 8 (812) 439-95-05 · mirannia@yandex.ru
Always discuss trial participation with your own doctor first.
| National Medical Research Center of Oncology named after N.N.Petrov Ministry of health of Russia | Saint Petersburg, Russian Federation, Russia | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06418789